BeOne's degrader BG-60366 appears to have been discontinued.
ApexOnco Front Page
Recent articles
21 April 2026
The disclosure comes as another of Arcus's TIGIT trials flops.
16 January 2026
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
16 January 2026
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
15 January 2026
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
14 January 2026
Three private biotechs enter clinical trials, one targeting KRAS.
14 January 2026
But PFS data are lacking, and there are questions about first and second-line plans.